KF
CORT icon

Krilogy Financial’s Corcept Therapeutics CORT Stock Holding History

Krilogy Financial’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$531K Buy
+6,111
New +$369K 0.02% 614
2018
Q4 		– Sell
-200
Closed -$3K – 237
2018
Q3 		$3K Buy
+200
New +$2.79K ﹤0.01% 671
2018
Q2 		– Sell
-200
Closed -$3K – 248
2018
Q1 		$3K Buy
+200
New +$3.71K ﹤0.01% 647

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Krilogy Financial's CORT Position: Q2 2026 in Review

Krilogy Financial opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 6,111 shares worth $531K. The stake represents 0.02% of the portfolio and ranks #614 among its holdings. This is a return to the name: Krilogy Financial previously reported a position in CORT as recently as Q3 2018.

Krilogy Financial first reported a position in CORT in Q1 2018 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Krilogy Financial held 6,111 shares of Corcept Therapeutics worth $531K as of Q2 2026.
  • Corcept Therapeutics was a new Krilogy Financial position in Q2 2026.
  • Corcept Therapeutics made up 0.02% of Krilogy Financial's portfolio in Q2 2026, its #614 holding.
  • Krilogy Financial first reported a position in Corcept Therapeutics in Q1 2018 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Krilogy Financial's 13F filing for Q2 2026, filed 27 Jul 2026.